The Day In Review: Another Indication For Herceptin From Genentech, Inc.

November 17, 2006 -- Genentech won an additional indication for Herceptin as an adjuvant in early-stage breast cancer; Johnson & Johnson bought stent-maker Conor Medsystems for $1.4 billion; Peregrine began a small Phase Ib trial of its cancer drug, bavituximab; Seattle Genetics will start a Phase I trial of a Hodgkin’s disease drug; Shire released positive data about two ADHD drug candidates; Dynavax traded sharply higher after Bear Stearns upped its rating; and Exelixis and Helsinn discontinued enrollment of a Phase III trial of becatecarin. The Centient Biotech 200™ moved over the 4000 mark, climbing 25 points to 4010, a rise of .64%. More details...